IgG4-Related Disease: Workup and Treatment
For suspected IgG4-related disease, initiate oral prednisolone 40 mg daily (or 0.5-0.6 mg/kg/day) for 2-4 weeks as first-line treatment after confirming diagnosis through tissue biopsy showing >10 IgG4+ plasma cells per high-power field, elevated serum IgG4, and characteristic imaging findings. 1, 2
Diagnostic Workup Algorithm
Step 1: Clinical Recognition
Look for these specific presentations:
- Pancreatic involvement: Mass or enlargement on CT, ductal abnormalities, exocrine insufficiency
- Biliary disease: Obstructive jaundice, cholangitis patterns on MRCP
- Multi-organ manifestations: Salivary/lacrimal gland swelling, retroperitoneal fibrosis, aortitis, lymphadenopathy, interstitial nephritis
- Absence of IBD (helps distinguish from PSC - IBD present in 70% of PSC vs 5.6% in IgG4-RD) 1
Step 2: Laboratory Testing
- Serum IgG4: Elevated in 50-80% of cases, but cannot diagnose in isolation 1
- IgG4/IgG1 ratio >0.24 improves specificity
- IgG4 >4x upper limit of normal is highly specific
- Critical caveat: 9-15% of PSC patients also have elevated IgG4 1
- Check for eosinophilia, polyclonal gammopathy, complement consumption 3
Step 3: Imaging
- MRCP is mandatory for all suspected cases 1
- Cross-sectional imaging (CT/MRI) to assess:
- Pancreatic abnormalities (long duct strictures >1/3 length, multifocal stricturing)
- Biliary tree patterns (4 types described)
- Other organ involvement
- PET scan can identify distant organ involvement (salivary/lacrimal glands) 1
Step 4: Tissue Diagnosis (Essential)
Pursue pathological confirmation in all cases 1:
- Endoscopic ampullary biopsy with IgG4 immunostaining (positive in 52-72% of cases) 1
- Look for: >10 IgG4+ plasma cells per high-power field with IgG4+/IgG+ ratio >40%
- Characteristic histology: lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis 1
- Liver/tissue biopsy if ampullary biopsy non-diagnostic 1
Step 5: Screen for Multi-Organ Disease
Systematically evaluate for other organ involvement - this is critical for prognosis and treatment planning 1:
- Pancreas, kidneys, retroperitoneum, lungs, salivary glands
- Multi-organ involvement predicts higher relapse rates (>60%) 1
Treatment Protocol
Initial Therapy (First-Line)
Oral prednisolone 40 mg daily for 2-4 weeks, then taper by 5 mg weekly over 8-12 weeks 1, 2
Alternative dosing for elderly or diabetic patients: 10-20 mg daily may be effective with fewer side effects 2
Assess response at weeks 2-4 using:
- Clinical improvement (resolution of jaundice, pain)
- Biochemistry (liver enzymes, bilirubin)
- Repeat imaging at weeks 4-8 1
Important: Lack of radiological improvement suggests either wrong diagnosis or fibrotic (non-inflammatory) phase 1
Maintenance Therapy (Critical to Prevent Relapse)
Relapse occurs in 60% of IgG4-SC patients and >40% of general IgG4-RD after steroid cessation 1. Therefore:
Introduce steroid-sparing immunosuppression during prednisolone taper 1, 2:
- Azathioprine 2 mg/kg/day (most commonly used)
- Alternatives: mycophenolate mofetil, 6-mercaptopurine
- Continue for up to 3 years, potentially longer 2
Maintenance prednisolone 5-7.5 mg daily reduces 3-year relapse from 58% to 23% (based on randomized data in IgG4-RD) 1
Refractory or Relapsing Disease
Rituximab is the preferred treatment for:
- Failure of first-line therapy
- Disease flare during steroid withdrawal
- Multi-system or complex disease 1
Dosing: 2 infusions of 1,000 mg rituximab 15 days apart, repeat every 6 months 2
- Response rate >95% in case series 1
- Inebilizumab (anti-CD19) is now FDA-approved and shows longer-lasting responses than rituximab 4, 5
Monitoring Strategy
Do NOT use serum IgG4 levels to monitor treatment or guide therapy 1 - it often falls with steroids but doesn't correlate with disease activity
Monitor with:
- Clinical symptoms
- Liver biochemistry
- Repeat imaging for mass lesions and cholangiopathy
- Regular follow-up for relapse detection 3
Critical Pitfalls to Avoid
Never diagnose IgG4-RD on serum IgG4 alone - requires comprehensive workup including histology 1
Always exclude malignancy - up to 8% of presumed hilar cholangiocarcinoma cases are actually IgG4-SC 1
Don't stop at initial steroid response - the high relapse rate mandates maintenance immunosuppression 1, 2
Refer complex cases to specialist centers for multidisciplinary review, especially with multi-organ involvement or suspected malignancy 1
Distinguish from PSC - presence of IBD, younger age, and lack of steroid response favor PSC over IgG4-RD 1